摘要
Journal of Medical VirologyVolume 95, Issue 11 e29235 LETTER TO THE EDITOR Risk factors of long COVID 6–12 months after infection with the Omicron variant among nonhospitalized patients Guangting Zeng, Corresponding Author Guangting Zeng [email protected] orcid.org/0000-0001-6844-3949 Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China Correspondence Guangting Zeng Email: [email protected]Search for more papers by this authorZanling Zhang, Zanling Zhang Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorLinlin Wang, Linlin Wang Department of Pharmacy, Cancer Center(Xiamen), Fudan University, Xiamen, ChinaSearch for more papers by this authorJianqiang Li, Jianqiang Li Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this author Guangting Zeng, Corresponding Author Guangting Zeng [email protected] orcid.org/0000-0001-6844-3949 Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China Correspondence Guangting Zeng Email: [email protected]Search for more papers by this authorZanling Zhang, Zanling Zhang Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorLinlin Wang, Linlin Wang Department of Pharmacy, Cancer Center(Xiamen), Fudan University, Xiamen, ChinaSearch for more papers by this authorJianqiang Li, Jianqiang Li Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this author First published: 06 November 2023 https://doi.org/10.1002/jmv.29235 Guangting Zeng and Zanling Zhang contributed equally to this study. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Luo J, Zhang J, Tang HT, et al. Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong. J Med Virol. 2023; 95:e28862. 10.1002/jmv.28862 CASPubMedWeb of Science®Google Scholar 2Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023; 381:e74572. Google Scholar 3Wang Y, Zhao D, Xiao W, et al. Paxlovid reduces the risk of long COVID in patients six months after hospital discharge. J Med Virol. 2023; 95:e29014. 10.1002/jmv.29014 CASPubMedWeb of Science®Google Scholar 4Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21: 133-146. 10.1038/s41579-022-00846-2 CASPubMedWeb of Science®Google Scholar 5Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399: 814-823. 10.1016/S0140-6736(22)00089-7 PubMedWeb of Science®Google Scholar 6Ayoubkhani D, Bosworth ML, King S, et al. Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: community-based, matched cohort study. Open Forum Infect Dis. 2022; 9: c464. 10.1093/ofid/ofac464 Google Scholar 7Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N Engl J Med. 2022; 387: 374-376. 10.1056/NEJMc2206711 PubMedWeb of Science®Google Scholar Volume95, Issue11November 2023e29235 ReferencesRelatedInformation